Ruboxistaurin
Ruboxistaurin
Ruboxistaurin (pronounced roo-box-i-stawr-in) is a type of pharmaceutical drug specifically designed to inhibit protein kinase C (PKC) beta, an enzyme that plays a significant role in the development of complications in diabetes. The drug is also known by its trade name, Arxxant.
Etymology
The name "Ruboxistaurin" is a coined term, with no specific etymological roots. It is a common practice in the pharmaceutical industry to create unique names for new drugs.
Usage
Ruboxistaurin is primarily used in the treatment of diabetic retinopathy, a diabetes complication that affects the eyes. It works by inhibiting the PKC beta enzyme, which is overactive in people with diabetes and can lead to various complications.
Related Terms
- Diabetes: A group of metabolic diseases characterized by high blood sugar levels over a prolonged period.
- Protein kinase C (PKC): A family of protein kinase enzymes that are involved in controlling the function of other proteins.
- Diabetic retinopathy: A diabetes complication that affects the eyes, caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina).
- Pharmaceutical drug: A drug used to diagnose, cure, treat, or prevent disease.
External links
- Medical encyclopedia article on Ruboxistaurin
- Wikipedia's article - Ruboxistaurin
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski